Compare Mesoblast Limited (MESO) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Wix.Com Ltd — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Wix.Com Ltd trades at $74.13 (market cap $3.11B). The key difference: Wix.Com Ltd is the larger of the two by market cap, and Wix.Com Ltd is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Wix.Com Ltd for 62 Days on average.
| MESO | WIX | |
|---|---|---|
Market Cap | $1.75B | $3.11B |
Volume | 239,027 | 809,286 |
Sector | Health | Technology |
52-Week High | $20.96 | $145.54 |
52-Week Low | $13.19 | $40.43 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | $1.83B | $4.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Wix stock trades at $72.97, down 1.27% today, amid a bearish technical signal and mixed earnings. Recent quarters show volatility with a Q1 2026 miss but a Q2 beat. Revenue growth is solid, reaching $1.99B in 2025, but profitability remains weak with a negative net income margin. The stock faces headwinds from a securities class action lawsuit, with multiple law firms announcing deadlines in late September 2026.
The outlook is cautious; analyst consensus is bullish with a $77 price target, but high valuation ratios and legal risks offset growth potential. Investors should weigh strong revenue trends against profitability challenges and near-term sentiment pressure from litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
